Cutera is expanding access to its AviClear, the FDA-cleared 1726 nm laser, by launching its Residency Program on Sept. 24. The program integrates the modality and other Cutera technology into dermatology training programs across North America for the long-term treatment of mild, moderate and severe acne. While this exposes aspiring dermatologists to new devices, it also gives them the opportunity to diversify their credentials through research opportunities as future professionals.
Through this program, the 24-month partnership with universities provides education on the laser device to students who are currently earning their certifications. Available in residency programs, the curriculum covers how to integrate the technology in practice and structured clinical training, per a Sept. 24 press release.
This article is only available to registered users.
Log In to View the Full Article
Cutera is expanding access to its AviClear, the FDA-cleared 1726 nm laser, by launching its Residency Program on Sept. 24. The program integrates the modality and other Cutera technology into dermatology training programs across North America for the long-term treatment of mild, moderate and severe acne. While this exposes aspiring dermatologists to new devices, it also gives them the opportunity to diversify their credentials through research opportunities as future professionals.
Through this program, the 24-month partnership with universities provides education on the laser device to students who are currently earning their certifications. Available in residency programs, the curriculum covers how to integrate the technology in practice and structured clinical training, per a Sept. 24 press release.
Alongside education, it creates collaboration opportunities as these students develop their careers as clinicians, positioning them in publications, research, podium presentations and exploration of new clinical indications for the Cutera brand.
The 1726 nm wavelength laser was FDA-cleared in March 2022 following extensive clinical trials and is currently undergoing research, joined by these pupils, exploring its implication beyond acne, including indications tied to the sebaceous gland, sebaceous hyperplasia, hidradenitis suppurativa, oily skin and pore size.
"Residents will now have early access to cutting-edge technology like AviClear, giving them hands-on experience with the future of acne care," said Ashish C. Bhatia, M.D., FAAD, co-director of Dermatologic, Laser and Cosmetic Surgery at Oak Dermatology. "At the same time, this partnership opens the door to exciting new research opportunities into sebaceous-based conditions such as sebaceous hyperplasia and hidradenitis suppurativa, expanding what's possible in dermatologic care."
These future dermatologists will not be limited to the 1726 nm laser either, with the program exposing them to Cutera's broader technology portfolio to explore other modalities, techniques and capabilities. Cutera is currently accepting applications from universities and programs interested in joining the Cutera Residency Program.
"Our goal is to empower the next generation of dermatologists through education and innovation," said Taylor Harris, CEO of Cutera. "By introducing AviClear into residency programs, we're advancing clinical training while reinforcing our commitment to pioneering solutions that shape the future of dermatology and improve lives."
